These Promising Clinical Results Could Be Huge for Amgen Investors
11/9 13:05
Amgen (NASDAQ: AMGN) recently shared data from its Phase 3 trial of tezepelumab, which it is developing in collaboration with AstraZeneca (NASDAQ: AZN). Tezepelumab was shown to be very effective in reducing "exacerbations and helping lung function and nasal symptoms in patients...